Pharmaceutical Technology1 天
H-1337 by D. Western Therapeutics Institute for Open-Angle Glaucoma: Likelihood of Approval
H-1337 is under clinical development by D. Western Therapeutics Institute and currently in Phase II for Open-Angle Glaucoma.
Nature4 个月
The genetics of open-angle glaucoma: The story of GLC1A and myocilin
A linkage analysis study was performed on a single large family with juvenile-onset primary open-angle glaucoma (POAG). This led to the recognition that there was a region of chromosome lq that ...
Health on MSN2 个月
What To Know about Open-Angle Glaucoma
Open-angle glaucoma is an eye disease that causes a gradual loss of vision. It is the most common type of glaucoma, a set of ...
Medscape13 天
Study Finds Association Between Statins and Glaucoma
People with high cholesterol taking statins have a higher prevalence of glaucoma than those with elevated cholesterol but not ...
ophthalmologytimes18 天
Iantrek, Inc. announces 1-Year outcomes from the CREST Registry for bio-interventional ...
Iantrek’s CREST Registry reports 1-year outcomes for a bio-interventional glaucoma treatment, demonstrating significant IOP ...
Pharmaceutical Technology1 天
Bimatoprost by Laboratoires Thea for Ocular Hypertension: Likelihood of Approval
Bimatoprost is under clinical development by Laboratoires Thea and currently in Phase III for Ocular Hypertension.
Glaucoma Surgical Devices Market to Hit Valuation of US$ 1,546 Million by 2033 | Astute ...
The glaucoma treatment landscape is shifting towards advanced surgical options, fueled by an aging population and greater ...